BRCA1/2 and PALB2 mutations were found in 5%–6% of patients with PDAC who were unselected for mutational status, whereas higher rates of 5%–19% were found in the high‐risk populations, such as Ashkenazi Jews and those with family histories of pancreatic, ovarian, or breast cancer [9]. This evidence concerns the gene BRCA1 and breast carcinoma.